Condition: Irritable Bowel Syndrome · Gastrointestinal Diseases · Colonic Diseases, Functional · Sponsor: EP Plus Group Sdn Bhd
The objective of this randomized, double-blind, placebo-controlled study is to evaluate the effectiveness of Skal Pro in alleviating symptoms, enhancing stool consistency, improving quality of life, and addressing psychological distress in individuals diagnosed with irritable bowel syndrome (IBS), as compared to those who receive no intervention.
This description comes directly from the study's public registry record.
Jonathan Khor · +60122888024 · jonathankhor@epplusgroup.com
Always discuss trial participation with your own doctor first.
| Hospital Universiti Sains Malaysia | Kubang Kerian, Kelantan, Malaysia | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06271538